Brazil's new cancer framework promises free advanced therapies through SUS and a push for domestic production

The promise being made in São Paulo is stark: cutting‑edge cancer treatments that can cost hundreds of thousands of reais per patient abroad are to become free at the point of care in Brazil’s public health system — and, as far as possible, made in Brazil.

On April 10, President Luiz Inácio Lula da Silva and Health Minister Alexandre Padilha took that promise a step closer to reality, at a ceremony at the Instituto do Coração’s new education and innovation center in São Paulo. There, the government formally sanctioned what it calls a new regulatory framework for cancer prevention and control in the Sistema Único de Saúde (SUS), Brazil’s universal public health system.

The measure amends a 2023 national cancer law (Law 14.758) and is based on a bill identified in Congress as PL 126/2025, which was approved by the Chamber of Deputies on March 24 and sent to the presidency two days later. It forces SUS to offer access to a basket of “new technologies against cancer” — including therapeutic vaccines, medicines, diagnostic tests, medical devices and advanced cell and gene therapies — and it rewires how Brazil regulates and buys those products.

In practice, the new framework does three big things.

First, it writes into law the principle that these technologies must be offered universally and free of charge through SUS. That sets a legal expectation that patients, regardless of income or where they live, can eventually claim access to some of the most complex and expensive cancer care now on the market.

Second, it orders Brazil’s health regulator, Anvisa, to give cancer products priority. For vaccines, drugs and other technologies covered by the law, the measure establishes accelerated timelines — 120 days for registration and 60 days for certain post‑registration changes, according to the legislative summary. Those compressed deadlines are important for pharmaceutical and biotech companies planning when they can bring products to the Brazilian market, and for patient groups that have long pressed for faster access.

Third, it explicitly turns cancer care into industrial policy. Public tenders will be allowed to prioritize products whose active ingredients or critical components are manufactured or developed in Brazil. The text ties this to the federal strategy known as the Complexo Econômico‑Industrial da Saúde (CEIS), an effort to rebuild domestic capacity in medicines, vaccines and medical equipment and reduce dependence on imports.

The law was still awaiting formal publication in the Diário Oficial da União, with an assigned law number and any presidential vetoes, as of Monday. Those details will determine the exact wording that Anvisa, the Health Ministry and purchasing officials must follow.

Politically, the government is using the cancer framework to showcase its broader narrative of “health sovereignty” and SUS pride. At the São Paulo event, Lula framed the push for advanced therapies as proof that a tax‑funded public system can match elite private care.

“A minha obsessão é provar que o Sistema Único de Saúde pode ser igual ou melhor do que qualquer instituição privada,” Lula said, according to the Health Ministry. “É isso que estamos fazendo: investindo em tecnologia de ponta para garantir que qualquer pessoa tenha direito ao tratamento mais moderno.”

Padilha, a physician and former lawmaker who returned to the Health Ministry in 2023, cast the move as unprecedented in scale. “O Governo do Brasil está fazendo o maior investimento já visto para o tratamento do câncer na história,” he said. “Estamos oferecendo o que há de melhor para a população em equipamentos de radioterapia e, com o novo marco, vamos desenvolver soluções ainda mais avançadas para o SUS.”

The stakes are high because of the sheer size of Brazil’s public oncology network. The ministry says SUS provided nearly 7 million chemotherapy sessions in 2024 through November, a jump of 79.5% compared with 2022. It also cites about 4 million mammograms in 2025, after expanding the age range for screening to women from 40 to 74 years old.

Layering advanced therapies — which often require individualized manufacturing, sophisticated logistics and intensive follow‑up — on top of this volume is a major operational and fiscal challenge. The 2023 law had already created a national cancer policy and a patient navigation program to organize care. The new amendment shifts the focus toward high‑tech access and the productive base needed to sustain it.

For Brazil’s pharmaceutical and biotech industries, the framework signals both opportunity and disruption. By allowing procurement to favor products with Brazilian‑made or Brazilian‑developed components, it could channel SUS’s purchasing power toward local manufacturers, public laboratories and research spin‑offs. That aligns with other CEIS initiatives that offer financing and partnerships for domestic production.

Multinational companies that currently supply many cancer drugs and diagnostic kits through imports may face a changing competitive landscape. To maintain or expand their share of the SUS market, they could be pushed to localize parts of their supply chains, transfer technology to Brazilian partners or invest in domestic R&D.

The regulatory changes will also test Anvisa’s capacity. Shorter review windows can speed patient access and make Brazil a more attractive launch market, but they require enough staff and expertise to scrutinize clinical data on therapies that can carry serious risks and uncertain long‑term outcomes. How the agency designs its fast‑track procedures — and whether it gets additional resources — will be closely watched by oncologists, industry and patient advocates.

Paying for the promised therapies is another unresolved question. Advanced cell and gene therapies and therapeutic vaccines can cost far more than conventional chemotherapy or radiotherapy. While the legislation points to research support from instruments such as the National Fund for Scientific and Technological Development (FNDCT), it does not, by itself, guarantee the sustained budget increases that large‑scale rollout through SUS would require. Any prioritization of domestic production in bidding processes will also have to be reconciled with Brazil’s general procurement law and trade commitments, a point lawyers are likely to scrutinize.

From Congress, supporters have framed the measure as a way to anchor SUS principles — universality, comprehensive care and equity — in the next generation of cancer medicine. Reporting from the Chamber of Deputies quotes the bill’s rapporteur, federal deputy Rosângela Reis, saying that the orientation toward free access and the expansion of vaccines, medicines and advanced therapies is fully consistent with those founding principles.

The immediate next steps are technical but decisive. The presidency must publish the law in the official gazette, making clear whether any parts were vetoed. Anvisa and the Health Ministry will then have to issue detailed regulations spelling out which products qualify for priority review, how the 120‑ and 60‑day clocks will work, and how procurement officers should apply domestic‑content preferences.

Only then will it become clear whether the framework is a turning point in Brazilian cancer care — or an ambitious promise that collides with budget limits, regulatory bottlenecks and industrial realities before it reaches patients.